New Faculty Achievements

A number of UT Southwestern Pathology faculty have released new publications, and have accomplished incredible achievements! Please join us in congratulating them for their accomplishments!


UTSW Paper Chosen for European Association of Cancer Research’s Top 10 Cancer Research Publications

Title: DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

The Model of Repairing Tumor Cells

PATH Faculty involved: Yang-Xin Fu, M.D., Ph.D.; Mingyi Chen, M.D., Ph.D.; Diego Castrillon, M.D., Ph.D.; Jian Qiao, M.D., Ph.D.

Journal: Cancer Cell



Favorable Phase II Trial Results for RCC and IVC-TT

Title: Neoadjuvant SAbR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus – Safety Lead-in Results of a Phase II Trial

PATH Faculty involved: Payal Kapur, M.D.

Journal: International Journal of Radiation Oncology*Biology*Physics



Mani Receives New DOD Award for Breast Cancer Research

PATH Faculty involved: Ram Mani, Ph.D.

Although known for his work in prostate cancer, Dr. Ram Mani has been awarded a new Department of Defense (DOD) grant, this time focusing his attention on another hormone-driven cancer. His research entitled "Targeting Treatment Resistance in Patients With Metastatic ER-Positive Breast Cancer" will receive almost $2.4M in funding for the next three years.

As nearly all patients with ER-positive metastatic breast cancer eventually develop resistance to both endocrine therapies and CDK4/6 inhibitors, treatment options for such women are extremely limited. Through this work, Drs. Mani and Prasanna Alluri, his co-investigator, plan to elucidate the mechanisms by which patients with breast cancer develop resistance to common targeted therapies and develop a new therapeutic strategy to overcome such resistance through BET inhibition. They propose to test the hypothesis that pharmacologic bromodomain and extraterminal domain (BET) inhibition, by blocking the addiction of treatment refractory estrogen receptor (ER)–positive breast tumors to bromodomain containing 4 (BRD4)–mediated reprogramming of transcriptional and DNA repair pathways, overcomes resistance to both endocrine therapies and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The project’s 2 specific aims are (1) to define the mechanisms by which BRD4 mediates reprogramming of transcriptional and DNA repair pathways in ER-positive breast cancer to confer resistance to endocrine therapies and CDK4/6 inhibitors and (2) to test if pharmacological BET inhibition overcomes resistance to both endocrine therapies and CDK4/6 inhibitors in in vivo xenograft models of breast cancer.